Adamas Pharmaceuticals, Inc. (ADMS)
Chart Events
Performance Outlook
| Previous Close | 5.1400 |
| Open | 5.1700 |
| Bid | 4.8900 x 1300 |
| Ask | 4.9100 x 1800 |
| Day's Range | 4.8600 - 5.4200 |
| 52 Week Range | 1.9000 - 9.1500 |
| Volume | 328,981 |
| Avg. Volume | 549,431 |
| Market Cap | 141.068M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.0300 |
| Earnings Date | Feb 23, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.56 |
- Benzinga
Adamas Pharmaceuticals: Q4 Earnings Insights
Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 22.89% over the past year to ($0.64), which missed the estimate of ($0.51). Revenue of $21,010,000 rose by 28.52% from the same period last year, which beat the estimate of $20,960,000. Looking Ahead Adamas Pharmaceuticals Sees FY 2021 Total Operating Expenses Expenses $115M-$130M How To Listen To The Conference Call Date: Feb 23, 2021 Time: 04:30 PM View more earnings on ADMS ET Webcast URL: https://edge.media-server.com/mmc/p/9kbxdi2b Technicals 52-week high: $9.15 Company's 52-week low was at $1.90 Price action over last quarter: Up 49.86% Company Profile Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 23, 2021A Preview Of Adamas Pharmaceuticals's Earnings© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Business Wire
Adamas Reports Fourth Quarter and Full Year 2020 Financial Results
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020, and recent corporate highlights.
- ACCESSWIRE
Adamas Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 23, 2021 / Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 23, 2021 at 4:30 PM Eastern Time.
